Active, not recruitingPhase 2NCT07028749
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
Studying Disorder of lipid metabolism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Marea Therapeutics
- Intervention
- MAR001(drug)
- Enrollment
- 216 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2025 – 2026
Study locations (30)
- Marea Site 328, Anniston, Alabama, United States
- Marea Site 329, Mobile, Alabama, United States
- Marea Site 313, Little Rock, Arkansas, United States
- Marea Site 306, Hamden, Connecticut, United States
- Marea Site 302, Boca Raton, Florida, United States
- Marea Site 307, Port Saint Lucie, Florida, United States
- Marea Site 310, Columbus, Georgia, United States
- Marea Site 319, Peachtree Corners, Georgia, United States
- Marea Site 317, Park Ridge, Illinois, United States
- Marea Site 325, Springfield, Illinois, United States
- Marea Site 301, Louisville, Kentucky, United States
- Marea Site 316, Baltimore, Maryland, United States
- Marea Site 330, Kansas City, Missouri, United States
- Marea Site 305, St Louis, Missouri, United States
- Marea Site 304, Great Neck, New York, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
The TIMI Study Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07028749 on ClinicalTrials.govOther trials for Disorder of lipid metabolism
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06695325Convenient Home Access for Routine Monitoring in Diabetes (Charm-D Study)Tameside General Hospital
- RECRUITINGPHASE1NCT06947304Evaluation of Miricorilant on Liver Fat in Patients With MASLDCorcept Therapeutics
- ENROLLING BY INVITATIONPHASE4NCT06845345Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)Carmen Dietvorst
- RECRUITINGPHASE3NCT06643130Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and DyslipidemiaJW Pharmaceutical
- ENROLLING BY INVITATIONNANCT06822621Functional Cereal Products and Contribution to the Regulation of Metabolism and Obesity-induced Chronic Low-grade Inflammation.Harokopio University
- ACTIVE NOT RECRUITINGPHASE3NCT06492291Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef ExtensionMerck Sharp & Dohme LLC
- RECRUITINGNCT06206759Vitamin C Administration and Triglycerides Level in Critical Care PatientsMeir Medical Center
- RECRUITINGNCT06383208Cardiovascular-Renal Adverse Prognosis Assessment System for Coronary Heart Disease With Chronic Kidney Disease Based on MetabolomicsChina-Japan Friendship Hospital